MaxCyte launched the MaxCyte STX Scalable Transfection System, which reduces the time and expense to develop relevant assays for high throughput screening. The technology enables the large scale transfection of primary cells, cell lines, and stem cells with multiple loading agents at the same time, resulting in more relevant screening systems. This scale and capability can reduce bottlenecks and improve the productivity of drug discovery groups, according to the company.
Published in Drug Discovery & Development magazine: Vol. 11, No. 11, November, 2008, p.9.
Filed Under: Drug Discovery
